

Arno de Wilde

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4076360/publications.pdf>

Version: 2024-02-01

26
papers

895
citations

623734

14
h-index

839539

18
g-index

28
all docs

28
docs citations

28
times ranked

1628
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of Bias in Reports of In Vivo Research: A Focus for Improvement. <i>PLoS Biology</i> , 2015, 13, e1002273.	5.6	240
2	Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 118.	6.2	129
3	Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort. <i>JAMA Neurology</i> , 2018, 75, 1062.	9.0	102
4	Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 143-151.	2.4	57
5	Multitracer model for staging cortical amyloid deposition using PET imaging. <i>Neurology</i> , 2020, 95, e1538-e1553.	1.1	55
6	Applying the ATN scheme in a memory clinic population. <i>Neurology</i> , 2019, 93, e1635-e1646.	1.1	51
7	The Alzheimer's disease drug development landscape. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 186.	6.2	49
8	Discordant amyloid- β PET and CSF biomarkers and its clinical consequences. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 78.	6.2	40
9	Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 72.	6.2	34
10	Early Stages of Alzheimer's Disease: Evolving the Care Team for Optimal Patient Management. <i>Frontiers in Neurology</i> , 2020, 11, 592302.	2.4	23
11	Long-term outcome after aneurysmal subarachnoid hemorrhage—risks of vascular events, death from cancer and all-cause death. <i>Journal of Neurology</i> , 2014, 261, 309-315.	3.6	22
12	PET and CSF amyloid- β status are differently predicted by patient features: information from discordant cases. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 100.	6.2	21
13	Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project. <i>Alzheimer's and Dementia</i> , 2019, 15, 1458-1467.	0.8	18
14	Genetic variants associated with type 2 diabetes and adiposity and risk of intracranial and abdominal aortic aneurysms. <i>European Journal of Human Genetics</i> , 2017, 25, 758-762.	2.8	13
15	Stress in Patients With (Un)ruptured Intracranial Aneurysms vs Population-Based Controls. <i>Neurosurgery</i> , 2019, 84, 1065-1071.	1.1	11
16	Added value of amyloid PET in individualized risk predictions for MCI patients. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 529-537.	2.4	8
17	[IC β 005]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOID- β AND [¹⁸ F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS. <i>Alzheimer's and Dementia</i> , 2017, 13, P13.	0.8	1
18	P3-142: Alzheimer's biomarkers in daily practice (ABIDE): Study design. , 2015, 11, P679-P680.		0

#	ARTICLE	IF	CITATIONS
19	P1-297: The Diagnostic Value of Amyloid Pet in an Unselected Cohort of Memory Clinic Patients. , 2016, 12, P534-P535.		0
20	ICâ€Pâ€011: The Diagnostic Value of Amyloid Pet in an Unselected Cohort of Memory Clinic Patients. Alzheimer's and Dementia, 2016, 12, P19.	0.8	0
21	[P2â€“207]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOIDâ€² AND [¹⁸ F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS. Alzheimer's and Dementia, 2017, 13, P688.	0.8	0
22	[DTâ€01â€02]: THE IMPACT OF AMYLOID PET ON DIAGNOSIS AND PATIENT MANAGEMENT IN AN UNSELECTED MEMORY CLINIC COHORT: THE ABIDE PROJECT. Alzheimer's and Dementia, 2017, 13, P1474.	0.8	0
23	O2â€04â€02: LONGITUDINAL COGNITIVE TRAJECTORIES OF PATIENTS WITH DISCORDANT CSF AND PET AMYLOID BIOMARKERS. Alzheimer's and Dementia, 2018, 14, P621.	0.8	0
24	O3â€13â€06: TAKING AMYLOID PET INTO THE CLINIC: INDIVIDUALIZED RISK PREDICTION IN MCI PATIENTS â€” THE ABIDE PROJECT. Alzheimer's and Dementia, 2018, 14, P1058.	0.8	0
25	The Importance of Phase 2 in Drug Development for Alzheimerâ€™s Disease. , 2022, , 150-161.		0
26	An accurate diagnosis contributes to delayed institutionalization and mortality: The ABIDE Project. Alzheimer's and Dementia, 2021, 17, .	0.8	0